Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05276050 · ClinicalTrials.gov registry record · NA

Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)

A NA study of Schizophrenia and Smoking Cessation, sponsored by The University of Texas Health Science Center, Houston.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05276050 is a NA study of Schizophrenia and Smoking Cessation that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 50 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05276050, a NA study of Schizophrenia and Smoking Cessation, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation. Smoking and brain functional connectivity changes will be assessed at baseline, different stages of rTMS and/or follow-ups.

Interventions

  • DEVICE active H-coil delivered rTMS
  • DEVICE active F8-coil delivered rTMS

Study Locations (1)

Texas

  • The University of Texas Health Science Center, Houston - Houston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-06-01
Est. Completion 2027-01-30
Phase NA

What the Registry Record Tells You About NCT05276050

The ClinicalTrials.gov registry entry for NCT05276050 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which active H-coil delivered rTMS is the first listed.

NCT05276050 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05276050 about?

NCT05276050 is a clinical study titled "Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)". Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation. Smoking and brain functional connectivity changes will be assessed at baseline, different stages of rTMS an...

What is the current status of trial NCT05276050?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-06-01. Estimated completion is 2027-01-30.

What conditions does trial NCT05276050 study?

This clinical trial studies the following conditions: Schizophrenia, Smoking Cessation, Nicotine Addiction.

What interventions are being tested in trial NCT05276050?

The interventions under investigation include: active H-coil delivered rTMS (DEVICE), active F8-coil delivered rTMS (DEVICE).

Who is sponsoring clinical trial NCT05276050?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05276050 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.